New registry aims to uncover risks of common transplant drug in pregnancy
NCT ID NCT01733082
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This registry follows pregnant women who have taken mycophenolate, a drug used to prevent organ rejection and treat autoimmune diseases. Researchers will collect data on pregnancy complications and birth defects up to one year after birth. The goal is to better understand the drug's risks and improve safety counseling.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mycophenolate
- What this could lead to
- If successful, this registry will provide clearer data on the risks of mycophenolate during pregnancy, helping doctors and patients make safer treatment decisions.
- What could go wrong
- This is an observational registry, not a treatment trial, so it won't directly improve outcomes. Results depend on accurate reporting and may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART TRANSPLANTATION, KIDNEY TRANSPLANTATION, LIVER TRANSPLANTATION, AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Quintiles Outcome
RECRUITINGCambridge, Massachusetts, 02139, United States